RGC

Regencell Bioscience is a development-stage company in traditional-Chinese-medicine-based therapeutics with no commercial revenue in any year of its history. FY2025 produced an operating loss of -$3.77M and a net loss of -$3.58M, continuing an unbroken string of losses (-$1.35M to -$7.45M across FY2021-FY2025). With no revenue and an accumulated deficit of -$25.2M against just $4.86M of equity, this is a pre-product research enterprise, not an operating business that can be valued on fundamentals.

The scale and structure are deeply concerning for an investor. Total assets are only $5.76M (down 31.8%) and cash is just $2.42M (down 18.3%) against a -$3.11M annual operating cash burn — under a year of runway. Most strikingly, shares outstanding ballooned 3,700% to 494M, an extraordinary expansion (stock split and/or issuance) that, combined with the 19% single-day price drop, signals extreme volatility and structural instability in the equity. The -73.7% return on equity reflects losses against a shrinking equity base.